Viral pneumonias (eg. COVID-19) have unpredictable disease courses and can be extremely severe because of tissue damage induced by the virus or hyperactivation of the host immune system. The point-of-care (SEH) 24/7 fully automated flow analysis allows fast immune profiling to monitor deterioration of disease on the ward and ICU.
Prognostic models providing clinicians with survival probabilities based on for example patient and diseasecharacteristics can help them to tailor care better to individual patients’ needs. In this project, several key issues hindering imbedding of prediction models in daily clinical practice will be addressed.
Rapid point of care tests to determine infection and/or past infection are urgently needed in the current COVID-19 pandemic. Rapid point of care Antigen-tests and Antibody-tests can provide a major benefit, as they produce a result within 10-15 minutes
Accurate & complete gene sequencing in tumors is increasingly relevant for cancer diagnosis, prognosis and treatment decisions. Proof of principle of methodologies has been developed for improved genetic cancer diagnostics that empower personalised cancer treatment.
To treat or not to treat with adjuvant chemotherapy following surgery is a key question for stage II and III colon cancer patients. This project aims to better guide this decision by extensive DNA mutation profiling of colon cancer tissue as prognostic (disease recurrence) and predictive (treatment response) biomarker.
Wound deepening through a lack of blood circulation in the affected skin, frequently occurs after burn injury and is associated with an adverse outcome. In this project it will be unveiled how certain white blood cells cause wound deepening and will test therapies that inhibit this process to improve the outcome.
This project is aimed at designing bioelectronic medicines to control inflammatory biological processes and treat Inflammatory bowel disease (IBD) by applying electrical impulses.
Thrombosis-related diseases account for approximately one in four deaths worldwide. However, current treatment does not fully protect against recurrent thrombosis and can cause bleeding as severe side effect. In this project a novel 3-in-1 test will be created for individual risk stratification and personalised management of antithrombotic therapy.
This project focuses on developing a blood-based biomarker panel for detection of NASH-induced fibrosis. The aim is to translate a set of candidate biomarkers into a non-invasive diagnostic tool for NASH patients.
Exacerbations are pivotal events in the progression of chronic obstructive pulmonary disease (COPD) and are associated with significant morbidity and mortality. Early diagnostic biomarkers for exacerbations, enabling early and targeted interventions, are currently lacking. This project aims to explore (bio)markers that are predictive of (preclinical) exacerbation and/or respiratory tract infection.